Clinical trials: Blood Plasma Therapy
Multiple Myeloma
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care
This study aims to compare how belantamab behaves in the body when given as an injection under the skin (SC) versus into a vein (IV) in participants with multiple myeloma who are receiving standard of care treatment, to enable…
- Trial name
- DynaMMic-2 (NCT07742527)
- Testing
- Belantamab SC, Belantamab IV, Recombinant Human Hyaluronidase PH20 (rHuPH20)
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who…
- Trial name
- KarMMa-9 (NCT06045806)
- Testing
- idecabtagene vicleucel, Lenalidomide, Fludarabine
- Where
- 101 sites in United States, Australia and 16 more
- Volunteers
- 79 people
- Sponsor
- Celgene
Multiple Myeloma
A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance
A prospective, multicentre, post-authorisation observational study. The objective of this study is assess the response of renal function in clinical practice to anti-multiple myeloma therapy in patients with relapsed MM and CrCl…
- Trial name
- MIR50 (NCT02849444)
- Testing
- Anti-myeloma treatment at physician discretion
- Where
- 40 sites in Spain
- Volunteers
- 326 people
- Sponsor
- Celgene
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Multiple Myeloma
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by…
- Trial name
- CARTITUDE-5 (NCT04923893)
- Testing
- Bortezomib, Dexamethasone, Lenalidomide
- Where
- 136 sites in United States, Argentina and 24 more
- Volunteers
- 743 people
- Sponsor
- Janssen Research & Development, LLC
AL Amyloidosis
Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
The goal of this clinical trial is to learn if Equecabtagene Autoleucel(Eque-cel), a Chimeric Antigen Receptor T-cell (CAR-T) therapy, works to treat severe Light Chain (AL) Amyloidosis in newly diagnosed adults with Mayo Stage…
- Trial name
- NCT07055724
- Testing
- Eque-cel CAR-T Therapy
- Volunteers
- 17 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Multiple Myeloma
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with…
- Trial name
- NCT02605356
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Bortezomib, Dexamethasone
- Where
- 58 sites in United States, Australia and 9 more
- Sponsor
- Bayer
Multiple Myeloma
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
The purpose of the study is to compare the efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and dexamethasone to placebo in combination with bortezomib and dexamethasone in the treatment of patients…
- Trial name
- NCT01470131
- Testing
- Masitinib, Bortezomib, Dexamethasone
- Where
- 13 sites in United States, France
- Volunteers
- 147 people
- Sponsor
- AB Science
Multiple Myeloma
A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)
In this study, people with MM will be treated with ixazomib citrate according to their clinic's standard practice. The main aim of the study is to check for side effects from ixazomib citrate.
- Trial name
- NCT04840680
- Testing
- No Intervention
- Where
- 20 sites in South Korea
- Volunteers
- 191 people
- Sponsor
- Takeda
Multiple Myeloma
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
The primary objective of this observational study is to document and describe current treatment regimens and disease progression of patients with Multiple Myeloma (MMY).
- Trial name
- NCT01241396
- Testing
- Any MMY treatment
- Where
- 159 sites in Algeria, Austria and 19 more
- Volunteers
- 2,396 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Multiple Myeloma
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
- Trial name
- MajesTEC-2 (NCT04722146)
- Testing
- Teclistamab, Daratumumab, Pomalidomide
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 140 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Myeloma Registry Platform (MYRIAM)
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics…
- Trial name
- MYRIAM (NCT03308474)
- Testing
- Routine care as per site standard.
- Where
- Germany
- Volunteers
- 2,200 people
- Sponsor
- iOMEDICO AG
Multiple Myeloma, Relapsed Cancer
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.
- Conditions
- Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease
- Trial name
- NCT05641324
- Testing
- ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab
- Where
- 11 sites in Denmark, France and 3 more
- Volunteers
- 4 people
- Sponsor
- Anaveon AG
Multiple Myeloma
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Multiple myeloma (MM) accounts for more than 10% of all blood cancers and 1% of all cancers. The purpose of this study is to assess how safe lemzoparlimab is and how lemzoparlimab moves through the body of adult participants with…
- Trial name
- NCT04895410
- Testing
- Lemzoparlimab, Dexamethasone, Carfilzomib
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 8 people
- Sponsor
- AbbVie
Relapsed or Refractory Multiple Myeloma
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone
- Trial name
- SELECT (NCT04191616)
- Testing
- Carfilzomib, Dexamethasone, Pomalidomide
- Where
- 46 sites in United States, Denmark and 6 more
- Volunteers
- 54 people
- Sponsor
- Amgen
Multiple Myeloma
A Study of NINLARO® in Chinese Adults With Multiple Myeloma
The main aim of this study is to check side effects and results in adults with multiple myeloma after switching from a bortezomib/carfilzomib -based to an Ixazomib-based treatment.
- Trial name
- NCT05013190
- Testing
- No intervention
- Where
- 12 sites in China
- Volunteers
- 72 people
- Sponsor
- Takeda
Multiple Myeloma
A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
The purpose of this study is to allow patients to receive VELCADE™ (bortezomib) for Injection who experienced progressive disease(PD) while receiving high-dose dexamethasone from the M34101-039 study.
- Trial name
- NCT00063726
- Testing
- bortezomib
- Where
- 76 sites in United States, Austria and 11 more
- Volunteers
- 600 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Renal Impairment, Multiple Myeloma
PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function
This was a multicenter study of the pharmacokinetics (PK) of melphalan during treatment with melflufen and dexamethasone in patients with relapsed refractory multiple myeloma (RRMM) and impaired renal function.
- Trial name
- BRIDGE (NCT03639610)
- Testing
- Melflufen, Dexamethasone
- Where
- 10 sites in Czechia, Greece and 1 more
- Volunteers
- 35 people
- Sponsor
- Oncopeptides AB
AL Amyloidosis
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04504825
- Testing
- CAEL-101, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
- Where
- 90 sites in United States, Australia and 17 more
- Volunteers
- 125 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Low Back Pain
A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain
To evaluate and compare the effectiveness of 3 different injection treatments on multifidus atrophy and lower back pain.
- Trial name
- NCT03618979
- Testing
- PPP treatment, PRP treatment, PRP and PL Combo treatment
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Regenexx, LLC